Comparative Pharmacology
Head-to-head clinical analysis: CETROTIDE versus DEGARELIX ACETATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CETROTIDE versus DEGARELIX ACETATE.
CETROTIDE vs DEGARELIX ACETATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cetrorelix is a synthetic decapeptide with gonadotropin-releasing hormone (GnRH) antagonistic activity. It competitively blocks GnRH receptors on the pituitary gland, reducing the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH).
Gonadotropin-releasing hormone (GnRH) receptor antagonist; competitively and reversibly binds to GnRH receptors in the anterior pituitary, rapidly suppressing luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion, thereby reducing testosterone production.
0.25 mg subcutaneously once daily starting on day 7 of ovarian stimulation and continuing until the day of hCG administration.
Subcutaneous injection: 240 mg loading dose (two 120 mg injections) on day 1, followed by 80 mg every 28 days.
None Documented
None Documented
Terminal elimination half-life is approximately 36 hours after subcutaneous administration. This long half-life supports once-daily dosing for continuous GnRH antagonist effect.
Terminal elimination half-life is approximately 43-73 days after subcutaneous administration, reflecting slow release from the depot formulation.
Primarily renal excretion of unchanged drug (approx. 40-50%) and metabolites; remainder excreted in feces via biliary elimination. Total recovery in urine and feces accounts for >90% of dose.
Renal elimination accounts for approximately 20-30% of the dose as unchanged drug; fecal elimination accounts for 70-80% primarily as metabolites.
Category C
Category C
GnRH antagonist
GnRH antagonist